Literature DB >> 11858876

Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA.

Juliana Cassataro1, Carlos A Velikovsky, Guillermo H Giambartolomei, Silvia Estein, Laura Bruno, Axel Cloeckaert, Raul A Bowden, Moisés Spitz, Carlos A Fossati.   

Abstract

A study was conducted to evaluate the immunogenicity of the Brucella melitensis ribosome recycling factor (RRF)-homologous protein (CP24). The CP24 gene was cloned, expressed in Escherichia coli and purified. The resulting purified recombinant protein (rCP24) produced delayed-type hypersensitivity (DTH) reactions in B. melitensis-infected mice but not in naive controls. Thus, we decided to characterise the immune responses generated with DNA vaccination (pcDNACP24) or immunisation with the rCP24 in adjuvant. Animals injected with pcDNACP24 exhibited a dominance of IgG2a to IgG1 while mice injected with rCP24 developed a higher response of IgG1 than IgG2a. Both immunisation protocols were capable of eliciting CP24-specific gamma interferon (IFN-gamma) producing cells. Spleen cells from pcDNACP24-immunised mice did not produce interleukin (IL)-4, IL-10 or up-regulation of IL-2 mRNA. Cells from rCP24-immunised mice produced IL-10, up-regulated IL-2 mRNA but did not produce IL-4. Neither immunisation with purified CP24 nor injection of pcDNACP24 protected mice against challenge with live smooth B. melitensis. However, the potential of CP24 for a Brucella diagnostic test based on an in vitro antigen (Ag)-specific IFN-gamma production or DTH test would be worth testing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858876     DOI: 10.1016/s0264-410x(01)00498-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice.

Authors:  Deyan Luo; Bing Ni; Peng Li; Wei Shi; Songle Zhang; Yue Han; Liwei Mao; Yangdong He; Yuzhang Wu; Xiliang Wang
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Immunogenicity and protective potential of a bacterially expressed recombinant dihydrolipoamide succinyltransferase (rE2o) of Brucella abortus in BALB/c mice.

Authors:  Shailendra Kumar Verma; Shikha Jain; Subodh Kumar
Journal:  World J Microbiol Biotechnol       Date:  2012-04-22       Impact factor: 3.312

3.  Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; M M Kahl-McDonagh; T A Ficht
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

4.  A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Silvia de la Barrera; Silvia M Estein; Laura Bruno; Raúl Bowden; Karina A Pasquevich; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Interaction of RRF and EF-G from E. coli and T. thermophilus with ribosomes from both origins--insight into the mechanism of the ribosome recycling step.

Authors:  V Samuel Raj; Hideko Kaji; Akira Kaji
Journal:  RNA       Date:  2005-01-20       Impact factor: 4.942

6.  Diagnostic usefulness of antibodies against ribosome recycling factor from Brucella melitensis in human or canine brucellosis.

Authors:  Juliana Cassataro; M Victoria Delpino; Carlos A Velikovsky; Laura Bruno; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

7.  Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria.

Authors:  M Victoria Delpino; Silvia M Estein; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.